Bioavailability of Methadone After Sleeve Gastrectomy: A Planned Case Observation  by Strømmen, Magnus et al.
Clinical Therapeutics/Volume 38, Number 6, 2016
Case Report
Bioavailability of Methadone After Sleeve
Gastrectomy: A Planned Case Observation
Magnus Strømmen, RN, MSc1,2; Arne Helland, MD3,4; Ba˚rd Kulseng, MD, PhD1; and
Olav Spigset, MD, PhD3,4
1Centre for Obesity Research, Clinic of Surgery, St. Olav University Hospital, Trondheim,
Norway; 2Department of Neuroscience, NTNU, Norwegian University of Science and Technology,
Trondheim, Norway; 3Department of Clinical Pharmacology, Clinic of Laboratory Medicine,
St. Olav University Hospital, Trondheim, Norway; and 4Department of Laboratory Medicine,
Children’s and Women’s Health, NTNU, Norwegian University of Science and Technology,
Trondheim, NorwayAccepted for publication April 19, 2016.
http://dx.doi.org/10.1016/j.clinthera.2016.04.033
0149-2918/$ - see front matter
& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ABSTRACT
Objective: Morbidly obese patients on opioid-
replacement therapy may be at risk for treatment refusal
with regard to bariatric surgery. However, patients on
opioid replacement may have the personal skills to
facilitate the lifestyle changes required for successful
outcomes after bariatric surgery. This planned case
observation assessed the effects of sleeve gastrectomy
on the pharmacokinetic properties of methadone.
Methods: A white woman in her 40s on methadone
maintenance therapy and with morbid obesity was
referred for bariatric surgery. Serial blood samples for
methadone concentration measurements were ob-
tained before and at 5 days and 1, 7, and 11 months
after surgery.
Findings: Serum methadone concentrations increased
from before to 5 days after surgery and continued to
increase for 7 months thereafter. The predose measurement
at 11 months postoperatively suggests a further increase
compared with the previous predose measurements.
Implications: Clinicians should beware the poten-
tial for altered effects of methadone after bariatric
surgery. We recommend that serum concentrations
be routinely measured pre- and postoperatively, and
that the dose be adjusted according to these measure-
ments and regular clinical assessments. (Clin Ther.
2016;38:1532–1536) & 2016 The Authors. Pub-
lished by Elsevier HS Journals, Inc.
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replacement, pharmacokinetics.1532INTRODUCTION
Although there are no absolute contraindications to
bariatric surgery,1 most bariatric surgeons consider
that patients with ongoing illicit drug use should not
undergo such procedures.2 The lack of clear
recommendations within this ﬁeld makes morbidly
obese patients on opioid-replacement therapy a sub-
group at risk for treatment refusal.
There is little evidence to provide guidance on these
matters. Of the few relevant studies that exist, one
found patients with past substance abuse to be at
higher risk for dropout during the assessment process
before bariatric surgery.3 However, a study evaluating
weight loss 2 years after gastric bypass found that
patients who previously and successfully had
participated in treatment for substance abuse (alcohol
or drugs) achieved more weight loss compared with
patients with no history of substance abuse.4 The
authors hypothesized that patients with such a history
can gain valuable insight into personal skills relevant
for lifestyle change, as well as draw strength from their
experience with abstinence support programs.
Both preclinical and clinical studies have reported that
chronic exposure to opioid μ-receptor agonists leads to
sweet taste preference.5 It is also known that patientsVolume 38 Number 6
M. Strømmen et al.entering methadone maintenance therapy gain weight:
One study found that women 2 years into treatment had
increased on average 17.5% in weight.6 Consequently,
occasional referrals of patients on methadone
maintenance are likely to occur in bariatric clinics.
Clinicians may be reluctant to provide bariatric
surgery in patients on opioid-replacement therapy, for
fear of adverse outcomes. Uncertainties concerning the
effects of the procedure on pharmacokinetics may con-
tribute to such hesitation. Several mechanisms of bariatric
surgery may inﬂuence the bioavailability of pharmaceut-
icals, such as shifts in gastric pH, changes in gastro-
intestinal transit time, reduced absorptive surface area,
and altered presystemic drug metabolism. The effects of
bariatric surgery on pharmacokinetic properties are
known for only a few medications.7 Neither methadone
nor buprenorphine, the drugs most commonly used for
opioid-replacement therapy, are among these.
This planned case observation is the ﬁrst systematic
evaluation of the possible effects of sleeve gastrectomy
on methadone pharmacokinetics.CASE DESCRIPTION
A white woman in her 40s on methadone maintenance
therapy and with morbid obesity was referred for
bariatric surgery at a Norwegian university hospital.
She had a 27-year history of illicit drug abuse and had
injected heroin for 10 years before she entered a
rehabilitation program that included opioid-replacement
therapy with methadone 10 years before presentation.
After starting methadone therapy, she had gained 30
kg in weight. At referral to hospital, her height was 159
cm, her weight was 127.8 kg, and her body mass index
(BMI) was 50.6 kg/m2. She presented with multiple
complications of morbid obesity, including type 2 dia-
betes mellitus, obstructive sleep apnea, and depression.
She also had hyperparathyroidism and was hepatitis B
and C positive. In addition to methadone 120 mg/d (a
dose that had been stable for several years), her drug
therapy consisted of metformin 1600 mg/d and sitaglip-
tin 100 mg/d for diabetes, fesoterodine 16 mg/d for
urinary incontinence, pregabalin 900 mg/d for neuralgia,
and lactulose as needed for constipation.
The patient underwent a multidisciplinary review,
including a psychiatric assessment, in the bariatric clinic.
She was informed about the lack of scientiﬁc evidence
concerning the effects on the pharmacokinetic properties
of methadone, and provided written consent to undergoJune 2016surgery, including being followed up for 15 years for the
evaluation of long-term effects. The authors also received
approval for performing the study from the regional
ethics committee. After completing a mandatory patient-
education program, the patient was scheduled for laparo-
scopic sleeve gastrectomy and followed a liquid very-low-
calorie diet the 3 weeks before surgery.
The patient’s preoperative weight and BMI were
117.0 kg and 46.3 kg/m2. Surgery took place with the
patient under general anesthesia, and the patient had
an epidural catheter placed for postoperative pain
relief. The need for epidural analgesia prolonged her
hospitalization, extending the regular stay of 1 to 2
days to 8 days. She received her regular dose of 120
mg methadone both on the day of surgery and on the
subsequent in-hospital days.
One year after surgery, her weight and BMI had
decreased to 92.1 kg and 36.4 kg/m2, respectively,
representing a 46.3% loss of her excess weight (using
the upper BMI limit for normal weight, i.e. 25 kg/m2,
as reference). Her physical functioning had improved
and she had stopped taking antidiabetic medication.
The methadone dose was kept unchanged at 120 mg/d
throughout the ﬁrst postoperative year.
Serial blood samples for methadone concentration
measurements were obtained at 8 days preoperatively, as
well as at 5 days, 1 month, and 7 months postoperatively.
Sampling took place at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8,
12, and 24 hours after methadone ingestion. Moreover, a
single sample was obtained 24 hours after methadone
ingestion at 11 months postoperatively. Serum concen-
trations of total methadone as well as of its enantiomersR-
methadone and S-methadone were measured with an LC/
MS method developed at our laboratory.8 Key
pharmacokinetic variables of methadone were calculated
by means of the pharmacokinetic analysis software
package Kinetica version 5.0 (Thermo Scientiﬁc,
Waltham, Massachusetts). The patient was genotyped
for the cytochrome P-450 (CYP) enzymes CYP2B6,
CYP3A4, and CYP3A5, which are involved in the
metabolism of methadone,9 by allele-speciﬁc polymerase
chain reaction (PCR).10,11RESULTS
The time–concentration curve of methadone in this
patient is presented in the Figure. In general, the serum
concentrations of methadone were increased from the
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Figure. Serum concentrations of methadone in a
woman undergoing bariatric surgery by
sleeve gastrectomy.
Clinical Therapeuticsand continued to increase during the ﬁrst 7 months
after surgery. The single predose measurement 11
months postoperatively suggested a further increase
compared with the previous predose measurements.
Key pharmacokinetic data are presented in the Table.
The AUC of the active enantiomer R-methadone
increased less than did that of total methadone, with
14%, 114%, and 163% increases at 5 days, 1 month,
and 7 months after surgery, respectively. In accordance
with this ﬁnding, the proportion of R-methadone of the
total methadone concentration decreased sharply shortly
after surgery, and then remained stable. The proportions
of R-methadone of the total methadone concentration
were 76% at t0 and 62% at Tmax preoperatively, and
65% at t0 and 52% at Tmax postoperatively. Genotyping
revealed the following genotypes: CYP2B6, *1/*1;
CYP3A4, *1/*1; and CYP3A5, *1/*3.
As methadone is known to prolong the QT interval
on ECG in a dose-related manner, increasing the risk
for torsades de pointes ventricular tachycardia,8 we
obtained pre- and postoperative ECGs. Immediately
preoperatively, the QT interval corrected for heart
rate (QTc) was 425 ms, whereas it was 435 ms at 10
months postoperatively.DISCUSSION
In this planned case observation, we observed marked
changes in the pharmacokinetic properties of meth-
adone after the patient had undergone sleeve gastrec-
tomy, with a large increase in drug exposure and a1534shorter Tmax compared with baseline. The total drug
exposure, as expressed by the AUC, increased pro-
gressively throughout the postoperative period, and 7
months postoperatively it was 3-fold the baseline
value. This large increase can be explained only by a
substantially greater bioavailability. The Tmax de-
creased from 2.5 hours before surgery to 1 hour at
7 months after surgery. The t1/2 increased slightly
immediately postoperatively, then it remained stable.
The active enantiomer, R-methadone, showed similar
changes, but to a somewhat lesser extent.
In most patients, methadone bioavailability is
480%; thus, the overall potential for increased
bioavailability of methadone would be expected to
be low and generally not exceed a 20% increase.
However, a large interindividual variability in bio-
availability, with values ranging from 36% to 100%,
has been described.9 Genotyping showed that the
patient had the CYP3A5 *1/*3 genotype, signifying
an increased metabolic capacity for CYP3A substrates
such as methadone compared with the general white
population.12 In patients expressing active CYP3A5,
the presence of this enzyme increases the presystemic
metabolism of CYP3A substrates, leading to lesser
bioavailability.12 This ﬁnding is in accordance with
the low preoperative serum concentration of
methadone in the present patient (a concentration
below the 10th percentile among patients taking a
dose of 120 mg/d, according to unpublished data from
our laboratory’s therapeutic drug monitoring
database, 2015). The potential for large increases in
the bioavailability of drugs metabolized by CYP3A
after bariatric surgery, particularly in patients who
express active CYP3A5, has been reported previously
for atorvastatin.13
Sleeve gastrectomy decreases gastric volume with-
out inducing malabsorption. No portion of the small
intestine is bypassed, and the pyloric function remains
intact.14 Thus, it may seem surprising that such a
procedure could dramatically inﬂuence drug bio-
availability. Logically, because no part of the intestine
is removed or bypassed, the amount of CYP3A in the
intestinal wall and thus the extent of presystemic
metabolism would be expected to be unaffected.
However, sleeve gastrectomy is associated with a
more rapid emptying of gastric contents into the
intestine after ingestion,15 a phenomenon often
referred to as "dumping." The decrease in Tmax
conﬁrms the occurrence of this mechanism in ourVolume 38 Number 6
Table. Pharmacokinetic variables based on the concentrations of total (R þ S) methadone and of the active










Total (R þ S) methadone
C0, nmol/L 508 645 1166 1481
Cmax, nmol/L 945 1414 2128 2564
Cmax/C0 ratio 1.86 2.19 1.82 1.73
Tmax, h 2.5 1.5 1.5 1.0
AUC0–24, nmol/L  h 14,368 20,198 34,920 44,983
AUC0–24, % increase
* 0 41 143 213
t½, h 29.3 36.5 37.1 37.2
R-methadone
C0, nmol/L 402 423 766 940
Cmax, nmol/L 616 748 1206 1379
Cmax/C0 ratio 1.53 1.77 1.57 1.47
Tmax, h 2.5 1.5 1.5 1.0
AUC0–24, nmol/L  h 10,453 11,946 22,401 27,460
AUC0–24, % increase
* 0 14 114 163
t½, h 43.9 48.4 59.4 54.8
*Compared to AUC0–24 preoperatively.
M. Strømmen et al.patient. Rapid gastric emptying after sleeve gas-
trectomy may lead to a substantially greater drug
concentration in the duodenum after methadone
intake. We hypothesize that the increased drug
concentration may overwhelm CYP3A enzyme
capacity in the intestinal wall and possibly also
during the ﬁrst pass through the liver, causing a
higher proportion of the drug to reach the systemic
circulation.
Other possible explanations for the observed phar-
macokinetic changes should be taken into consider-
ation. Systemic inﬂammation may downregulate the
expression of both CYP enzymes and drug trans-
porters such as p-glycoprotein and increase the plasma
concentration of the acute phase protein α1-acid
glycoprotein, to which methadone is highly bound.9
Such changes may possibly have contributed to the
increased serum concentration of methadone
immediately postoperatively. However, this concept
cannot explain the further increases in metha-
done concentration during the subsequent months.
Moreover, we cannot rule out the possibility thatJune 2016inadequate medication adherence contributed to the
observed changes. However, because the methadone
concentrations at t0 and t24 were almost identical in
all 4 sample series, nonadherence does not seem likely.
The patient’s considerable weight loss has reduced the
total volume of distribution of the methadone.
However, as the concentration at steady state is
primarily related to clearance and not to the volume
of distribution, the key question is whether a weight
loss like this could reduce clearance, such as via a
decrease in liver mass. The patient’s lean body mass
was reduced by 9.3% from 1 to 7 months
postoperatively. Even if the total liver mass would
be expected to have decreased by the same order of
magnitude, we consider that the contribution of
such an effect would explain only a small part of
the observed increases in the methadone con-
centration. Finally, to our knowledge, the patient
did not at any point use medications known to
inﬂuence CYP3A metabolism, which could other-
wise have inﬂuenced the pharmacokinetic pro-
perties of methadone.1535
Clinical TherapeuticsPre- and postoperative ECGs did not reveal a
signiﬁcant increase in the QT interval; however, the risk
for QT prolongation in such patients should deﬁnitively
be borne in mind as it is a known dose-dependent
adverse effect of methadone.8 A higher and more rapidly
occurring peak concentration might increase the
rewarding and intoxicating effects of methadone,
which could be detrimental in previous addicts, and
might even cause respiratory depression. Unfortunately,
we do not have systematic clinical observations of the
patient during the postoperative period.CONCLUSION
We conclude that sleeve gastrectomy has the potential
to signiﬁcantly increase the bioavailability of and
decrease the Tmax of methadone, probably due to
accelerated gastric emptying. This ﬁnding especially
applies to individuals with a low preoperative bio-
availability, such as that caused by genetically deter-
mined or pharmacologically induced increased
CYP3A metabolism. Clinicians should beware the
potential for altered drug effects of methadone after
bariatric surgery. We recommend that serum concen-
trations be routinely measured pre- and postopera-
tively, and that the dose be adjusted according to these
measurements and regular clinical assessments.CONFLICTS OF INTEREST
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